Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Comparative Study

Review

Clinical Trial

Randomized Controlled Trial

Multicenter Study

Clinical Trial, Phase III

Research Support, U.S. Gov't, Non-P.H.S.

Clinical Trial, Phase II

Research Support, U.S. Gov't, P.H.S.

Research Support, N.I.H., Extramural

Meta-Analysis

Systematic Review

Publication Year

From

Quick links

Individual year

2026

2025

2024

2023

2022

2019

2018

2016

2015

2012

2010

2007

2006

2005

2001

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Fulvestrant""[mesh_terms]

27 Results

Searching titles within these results

Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.

Aman U Buzdar, John F R Robertson

The Annals of pharmacotherapy 2006;40(9):1572-83

Full Text

Abstract

Small change - big consequence: The impact of C15-C16 double bond in a D‑ring of estrone on estrogen receptor activity.

Petr Vonka, Lucie Rarova, Vaclav Bazgier, Vlastimil Tichy, Tamara Kolarova, Jitka Holcakova, Karel Berka, Miroslav Kvasnica, Jana Oklestkova, Eva Kudova, Miroslav Strnad, Roman Hrstka

The Journal of steroid biochemistry and molecular biology 2023;233():106365

Free Full Text

Abstract

17beta-estradiol protects SH-SY5Y Cells against HIV-1 gp120-induced cell death: evidence for a role of estrogen receptors.

Rossella Russo, Michele Navarra, Jessica Maiuolo, Domenicantonio Rotiroti, Giacinto Bagetta, Maria Tiziana Corasaniti

Neurotoxicology 2005;26(5):905-13

Full Text

Abstract

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.

Vincenzo Quagliariello, Massimiliano Berretta, Matteo Barbato, Fabrizio Maurea, Maria Laura Canale, Andrea Paccone, Irma Bisceglia, Andrea Tedeschi, Marino Scherillo, Jacopo Santagata, Stefano Oliva, Christian Cadeddu Dessalvi, Pietro Forte, Cristiana D'Ambrosio, Tiziana Di Matola, Regina Parmentola, Domenico Gabrielli, Nicola Maurea

International journal of molecular sciences 2026;27(8):

Full Text

Abstract

Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.

Elsa Dalmau, Alejandra Armengol-Alonso, Montserrat Muñoz, Miguel Ángel Seguí-Palmer

Breast (Edinburgh, Scotland) 2015;23(6):710-20

Full Text

Abstract

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.

Vicky Makker, Maria M Rubinstein, Pooja Shah, Alexia Iasonos, Jason Konner, Seth Cohen, William Tew, Carol Aghajanian, Pier Selenica, Qin Zhou, Angela K Green, William A Zammarrelli, Britta Weigelt, Lora H Ellenson, Rashmi Chhetri-Long, Jade Loh, Vania Hom, Joseph Erinjeri, Iva Petkovska, Sarat Chandarlapaty, Rachel Grisham, Tiffany Troso-Sandoval

Clinical cancer research : an official journal of the American Association for Cancer Research 2025;31(11):2088-2096

Full Text

Abstract

Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.

Hirotaka Iwase, Yutaka Yamamoto

International journal of clinical oncology 2016;20(2):253-61

Full Text

Abstract

Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.

Sayem Miah, Edward Bagu, Raghuveera Goel, Yetunde Ogunbolude, Chenlu Dai, Alison Ward, Frederick S Vizeacoumar, Gerald Davies, Franco J Vizeacoumar, Deborah Anderson, Kiven Erique Lukong

BMC cancer 2019;19(1):78

Free Full Text

Abstract

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer.

Jun Ho Yi, In-Gu Do, Jiryeon Jang, Seung Tae Kim, Kyoung-Mee Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Jeeyun Lee

Scientific reports 2015;4():7592

Free Full Text

Abstract

Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.

G N Hortobagyi, F J Esteva

Breast (Edinburgh, Scotland) 2006;15(3):301-12

Full Text

Abstract

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.

Carla L Alves, Daniel Elias, Maria Lyng, Martin Bak, Tove Kirkegaard, Anne E Lykkesfeldt, Henrik J Ditzel

Clinical cancer research : an official journal of the American Association for Cancer Research 2018;22(22):5514-5526

Full Text

Abstract

Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

Fabrice André, Eva Ciruelos, Gabor Rubovszky, Mario Campone, Sibylle Loibl, Hope S Rugo, Hiroji Iwata, Pierfranco Conte, Ingrid A Mayer, Bella Kaufman, Toshinari Yamashita, Yen-Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, Anne-Sophie Longin, David Mills, Celine Wilke, Samit Hirawat, Dejan Juric

The New England journal of medicine 2019;380(20):1929-1940

Full Text

Abstract

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.

Preeti Narayan, Tatiana M Prowell, Jennifer J Gao, Laura L Fernandes, Emily Li, Xiling Jiang, Junshan Qiu, Jianghong Fan, Pengfei Song, Jingyu Yu, Xinyuan Zhang, Bellinda L King-Kallimanis, Wei Chen, Tiffany K Ricks, Yutao Gong, Xing Wang, Katherine Windsor, Steve Y Rhieu, Gerlie Geiser, Anamitro Banerjee, Xiaohong Chen, Francisca Reyes Turcu, Deb K Chatterjee, Anand Pathak, Jeffrey Seidman, Soma Ghosh, Reena Philip, Kirsten B Goldberg, Paul G Kluetz, Shenghui Tang, Laleh Amiri-Kordestani, Marc R Theoret, Richard Pazdur, Julia A Beaver

Clinical cancer research : an official journal of the American Association for Cancer Research 2022;27(7):1842-1849

Free Full Text

Abstract

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).

L Perey, R Paridaens, H Hawle, K Zaman, F Nolé, H Wildiers, M Fiche, D Dietrich, P Clément, D Köberle, A Goldhirsch, B Thürlimann

Annals of oncology : official journal of the European Society for Medical Oncology 2007;18(1):64-69

Free Full Text

Abstract

Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

J F Robertson, R I Nicholson, N J Bundred, E Anderson, Z Rayter, M Dowsett, J N Fox, J M Gee, A Webster, A E Wakeling, C Morris, M Dixon

Cancer research 2001;61(18):6739-46

Full Text

Abstract

Results: 1 – 15 / 27

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Fulvestrant""[mesh_terms]

Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.

Small change - big consequence: The impact of C15-C16 double bond in a D‑ring of estrone on estrogen receptor activity.

17beta-estradiol protects SH-SY5Y Cells against HIV-1 gp120-induced cell death: evidence for a role of estrogen receptors.

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.

Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.

Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.

Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer.

Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.

Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).

Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

Results for
""Fulvestrant""[mesh_terms]